Arrowhead Pharmaceuticals Eyes Major Stock Re-Rating Potential From Plozasiran Drug Candidate

Investors are closely monitoring clinical developments for Arrowhead's experimental therapy Plozasiran, which could significantly impact the biotech firm's valuation and market standing.